Device profile of the MobiusHD EVBA system for the treatment of resistant hypertension: overview of its mechanism of action, safety and efficacy

References

• Vaclavik J, Sedlak R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)–study protocol. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011;155(2):143–148.
   PubMed Web of Science ®Google Scholar
• Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9699):1423–1431.
   PubMed Web of Science ®Google Scholar
• Ventura HO, Mehra MR, Messerli FH. Desperate diseases, desperate measures: tackling malignant hypertension in the 1950s. Am Heart J. 2001;142(2):197–203.
   PubMed Web of Science ®Google Scholar
• Longland CJ, Gibb WE. Sympathectomy in the treatment of benign and malignant hypertension; a review of 76 patients. Br J Surg. 1954;41(168):382–392.
   PubMed Web of Science ®Google Scholar
• Bohm M, Mahfoud F, Sievert H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–1909.
   PubMed Web of Science ®Google Scholar
• Heuser RR, Mhatre AU, Buelna TJ, et al. A novel non-vascular system to treat resistant hypertension. EuroIntervention. 2013;9(1):135–139.
   PubMed Web of Science ®Google Scholar
• Bisognano JD, Bakris G, Nadim MK, et al., Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 58(7): 765–773. 2011.
   PubMed Web of Science ®Google Scholar
• Sobotka PA, Osborn JW, Paton JF. Restoring autonomic balance: future therapeutic targets. EuroIntervention. 2013;9(Suppl R):R140–8.
   PubMedGoogle Scholar
• Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152(16):1501–1504.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Bangalore S. Renal denervation for resistant hypertension? N Engl J Med. 2014;370(15):1454–1457.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Kandzari DE, O’Neill WW, et al., A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 370(15): 1393–1401. 2014.
   PubMed Web of Science ®Google Scholar
• Bohm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–1451.
   PubMed Web of Science ®Google Scholar
• Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335–2345.
   PubMed Web of Science ®Google Scholar
• Beige J, Jentzsch T, Wendt R, et al. Blood pressure after blinded, randomized withdrawal, and resumption of baroreceptor-activating therapy. J Hypertens. 2017;35(7):1496–1501.
   PubMedGoogle Scholar
• Groenland EH, Spiering W. Baroreflex amplification and carotid body modulation for the treatment of resistant hypertension. Curr Hypertens Rep. 2020;22(4):27.
   PubMed Web of Science ®Google Scholar
• Halim J, Lycke M, Van der Heyden J. Endovascular baroreflex amplification for resistant hypertension: what you need to know. Future Cardiol. 2020;16(3):151–158.
   PubMed Web of Science ®Google Scholar
• Gierthmuehlen M, Plachta DTT, Zentner J. Implant-mediated therapy of arterial hypertension. Curr Hypertens Rep. 2020;22(2):16.
   PubMed Web of Science ®Google Scholar
• van Kleef M, Bates MC, Spiering W. Endovascular baroreflex amplification for resistant hypertension. Curr Hypertens Rep. 2018;20(5):46.
   PubMed Web of Science ®Google Scholar
• Hering H Jr. (1866-1948)–pathologic physiologist. JAMA. 1965;193:957–958.
   PubMed Web of Science ®Google Scholar
• Chen CY, Bonham AC. Postexercise hypotension: central mechanisms. Exerc Sport Sci Rev. 2010;38(3):122–127.
   PubMed Web of Science ®Google Scholar
• Mancia G, L MA. Arterial baroreflexes in humans, In: Shepherd JT, Abboud FM, editors Handbook of physiology. The Cardiovascular System. Circulation. Bethesda (MD): Am Physiol Soc; 1983:168.
   Google Scholar
• Chapleau MW, Hajduczok G, Abboud FM. Peripheral and central mechanisms of baroreflex resetting. Clin Exp Pharmacol Physiol Suppl. 1989;15:31–43.
   PubMedGoogle Scholar
• Hauss WH, ARNDT T, DERLAM G. et al. [Effect of carotid sinus stimulation on the electroencephalogram]. Z Kreislaufforsch. 1954;43(23–24):831–840.
   PubMedGoogle Scholar
• Seagard JL, Gallenberg LA, Hopp FA, et al. Acute resetting in two functionally different types of carotid baroreceptors. Circ Res. 1992;70(3):559–565.
   PubMed Web of Science ®Google Scholar
• McCubbin JW, Green JH, Page IH. Baroceptor function in chronic renal hypertension. Circ Res. 1956;4(2):205–210.
   PubMed Web of Science ®Google Scholar
• Samson WK. AJP-regulatory, integrative and comparative physiology: into the future. Am J Physiol Regul Integr Comp Physiol. 2013;305(1):R1–3.
   PubMed Web of Science ®Google Scholar
• Mancia G, Parati G, Pomidossi G, et al. Arterial baroreflexes and blood pressure and heart rate variabilities in humans. Hypertension. 1986;8(2):147–153.
   PubMed Web of Science ®Google Scholar
• Scheffers IJ, Kroon AA, de Leeuw PW. Carotid baroreflex activation: past, present, and future. Curr Hypertens Rep. 2010;12(2):61–66.
   PubMed Web of Science ®Google Scholar
• Seravalle G, Dell’Oro R, Grassi G. Baroreflex activation therapy systems: current status and future prospects. Expert Rev Med Devices. 2019;16(12):1025–1033.
   PubMed Web of Science ®Google Scholar
• Zile MR, Abraham WT, Weaver FA, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. Eur J Heart Fail. 2015;17(10):1066–1074.
   PubMed Web of Science ®Google Scholar
• Halbach M, Abraham WT, Butter C, et al. Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. Int J Cardiol. 2018;266:187–192.
   PubMed Web of Science ®Google Scholar
• Peter DA, Alemu Y, Xenos M, et al., Fluid structure interaction with contact surface methodology for evaluation of endovascular carotid implants for drug-resistant hypertension treatment. J Biomech Eng. 134(4): 041001. 2012.
   PubMed Web of Science ®Google Scholar
• Bone JF. Animal anatomy and physiology. 3rd ed., Vol. xvi, Englewood Cliffs, N.J: Prentice-Hall; 1988. p. 572.
   Google Scholar
• Aspinall V. Essentials of veterinary anatomy and physiology. Edinburgh; New York: Elsevier Butterworth Heinemann; 2005. p. 248 p.
   Google Scholar
• Toorop RJ, Scheltinga MR, Ricco J-B, et al., Rationale of novel interventions for resistant hypertension. Eur J Vasc Endovascular Surg. 42(5): 557–559. 2011.
   PubMed Web of Science ®Google Scholar
• Muntner P, Davis BR, Cushman WC, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension. 2014;64(5):1012–1021.
   PubMed Web of Science ®Google Scholar
• Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967..
   PubMed Web of Science ®Google Scholar
• Spiering W, Williams B, Van der Heyden J, et al., Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet. 390(10113): 2655–2661. 2017.
   PubMed Web of Science ®Google Scholar
• Seagard JL, Hopp FA, Drummond HA, et al. Selective contribution of two types of carotid sinus baroreceptors to the control of blood pressure. Circ Res. 1993;72(5):1011–1022.
   PubMed Web of Science ®Google Scholar
• Chapleau MW, Hajduczok G, Abboud FM. Pulsatile activation of baroreceptors causes central facilitation of baroreflex. Am J Physiol. 1989;256(6 Pt 2):H1735–41.
   PubMedGoogle Scholar
• Fan W, Reynolds PJ, Andresen MC. Baroreflex frequency-response characteristics to aortic depressor and carotid sinus nerve stimulation in rats. Am J Physiol. 1996;271(6 Pt 2):H2218–27.
   PubMedGoogle Scholar
• Ramchandra R, Barrett CJ, Guild S-J, et al. Evidence of differential control of renal and lumbar sympathetic nerve activity in conscious rabbits. Am J Physiol Regul Integr Comp Physiol. 2006;290(3):R701–8.
   PubMed Web of Science ®Google Scholar